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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
1. To provide an overview of evidence from Cochrane systematic reviews of the effectiveness of TENS to reduce pain in adults with
chronic pain (excluding headache or migraine).
2. To provide an overview of evidence from Cochrane systematic reviews of the safety of TENS to reduce pain in adults with
chronic pain (excluding headache or migraine).
3. To identify possible sources of inconsistency in the approaches taken to evaluating the evidence related to TENS for chronic
pain (excluding headache or migraine) in the Cochrane Library with a view to recommending strategies to improve consistency.
4. To highlight areas of remaining uncertainty regarding the effectiveness of TENS for chronic pain (excluding headache or
migraine) with a view to recommending strategies to reduce any uncertainty.
B A C K G R O U N D
Description of the condition
Chronic pain is a common problem. When defined as pain of
greater than three months duration, prevalence studies indicate
that up to half the adult population suffer from chronic pain, and
10% to 20% experience clinically significant chronic pain (Smith
2008). In Europe, 19% of adults report long standing pain of
moderate to severe intensity with serious negative implications for
their social and working lives. Many of these people receive inade-
quate pain management (Breivik 2006). Chronic pain clearly im-
pacts the quality of life of those who experience it (Moore 2014a)
but also has a substantial economic impact on society, in terms
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of reduced productivity, participation and healthcare utilisation
(Gaskin 2012; Gustavsson 2012).
Chronic pain is a heterogenous phenomenon with a wide variety
of potential causes. These may include both somatic and neuro-
pathic pain conditions in which there is clear evidence of ongoing
peripheral tissue pathology, such as rheumatoid arthritis and di-
abetic neuropathy, as well as many other chronic pain problems,
such as fibromyalgia and chronic non-specific low back pain, in
which the relationship between peripheral tissue pathology and
clinical symptoms is less clear. It is likely that differentmechanisms
of pain production underpin these different types of chronic pain
(Ossipov 2006).
Description of the interventions
Transcutaneous Electrical Nerve Stimulation (TENS) is the ther-
apeutic application of electrical nerve stimulation over the skin. It
is primarily used for pain control in people with a plethora of acute
and chronic pain conditions. TENS units typically use adhesive
electrodes applied to the skin surface to apply non-invasive pulsed
electrical stimulation that can be modified in terms of frequency
(stimulation rate), intensity and duration (Johnson 2011). TENS
is commonly delivered in either high or low frequency modes.
High frequency may be defined as being greater than 50Hz (Sluka
2003), although a number of studies use frequencies at or above
100Hz (Moran 2011; Santos 2013; Sluka 2005). In contrast, low
frequency TENS is consistently defined as being 10Hz or less
(Bjordal 2003;Moran 2011; Sabino 2008). Low frequency TENS
is often used at higher intensities, eliciting muscle contraction,
while high frequency TENS has traditionally been used at lower
intensities. Modulated TENS applies stimulation across a range of
frequencies and may help to prevent the development of tolerance
to the electrical stimulation (Sluka 2013).
Intensity appears to be a critical factor in optimisingTENS efficacy
and it is thought that regardless of frequency of application, the
intensity needs to produce a strong, non-painful sensation which
ideally is titrated during treatment to maintain the intensity level
(Bjordal 2003;Moran 2011; Sluka 2013). Placement of electrodes
may also influence response although this issue is somewhat am-
biguous with local, related spinal segment and contralateral elec-
trode placement demonstrating an effect in both animal and hu-
man studies (Brown 2007; Chesterton 2003; Dailey 2013; Sabino
2008; Somers 2009). Timing of outcome measurement requires
considerationwhen analysingTENS studies as theory predicts that
any TENS analgesia induced should peak during or immediately
after use (Sluka 2013).
How the intervention might work
The process by which TENS-induced analgesia is produced is
thought to be multifactorial and encompasses likely peripheral,
spinal and supraspinal mechanisms. In a recent animal study,
the increased mechanical sensitivity caused by peripheral injec-
tion of serotonin (a substance naturally produced following in-
jury and inflammation) was decreased by application of TENS
(Santos 2013). Importantly, this analgesia was partly mediated
by peripheral mechanisms as pre-injection of a peripheral opioid
receptor blocker decreased the analgesia produced, implying the
TENS effect is mediated via activation of these peripheral recep-
tors (Santos 2013). A spinal effect for electrical stimulation was
initially demonstrated by Wall 1967 and was suggested to work
via the ’pain-gate’ mechanism initially proposed in 1965 (Melzack
1965). Pain gate theory proposes large diameter (Aβ) afferent fi-
bres (carrying sensations such as vibration, touch etc) inhibit no-
ciceptive traffic in the dorsal horn of the spinal cord, with a re-
sultant decrease in pain (Melzack 1965). Clearly, TENS applica-
tion and the resultant stimulation of afferent neural structures is
a source of considerable large diameter afferent activity and this
is therefore a plausible means of TENS induced analgesia. How-
ever, TENS is thought to have additional spinal segmental effects:
decreased inflammation induced dorsal horn neuron sensitisation
(Sabino 2008), altered levels of neurotransmitters such as gamma-
aminobutyric acid (GABA) and glycine, which are thought to be
involved in inhibition of nociceptive traffic (Maeda 2007; Somers
2009), and modulation of the activity of the cells which pro-
vide support and surround neurons (glial cells) in the spinal cord
(Matsuo 2014) have all been suggested means by which TENS
may produce analgesia at a spinal segmental level.
TENS also appears to have an effect on endogenous analgesia
mediated by higher centres of the nervous system. Descending
inhibitory activity relayed via the midbrain periaqueductal grey
(PAG) and the rostral ventral medulla (RVM) in the brainstem has
anti-nociceptive effects (Gebhart 2004). This PAG-RVM relayed
inhibition has been shown to be mediated via opioidergic path-
ways (Calvino 2006; Gebhart 2004). TENS-induced analgesia is
abolished with pre-injection of opioid receptor blockers in both
the PAG and RVM in rats with experimentally-induced peripheral
inflammation (DeSantana 2009; Kalra 2001), implying this may
be an operational pathway by which TENS contributes to anal-
gesia. Support for the effect of TENS on descending inhibitory
mechanisms in humans is provided by evidence of increased de-
scending modulation of pain in people with fibromyalgia during
TENS treatment compared to noTENS or placeboTENS (Dailey
2013). It is worth noting that low frequency and high frequency
TENS effects are mediated via µ and δ opioid receptor classes,
respectively. As such, the effects of low frequency TENS may be
limited in patients using opioids for pain relief as they primarily
act via µ-opioid receptor pathways (Sluka 2013). Given that phar-
macological management of neuropathic pain may involve opioid
medication, it is possible this may impact upon low frequency
TENS efficacy if used concurrently.
These descending inhibitory mechanisms have also been impli-
cated in placebo analgesia (the phenomena of improvements in
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pain which follow the delivery of an inert treatment). It is pos-
sible that the suggested mechanisms of TENS-induced analgesia
described above may not necessarily represent specific effects of
electrical stimulation but could result purely from the therapeutic
ritual of using a TENS unit.
Sham credibility issues in TENS trials
An issue regarding the credibility of sham conditions specifically
for TENS studies is whether the sham condition that is employed
uses controls adequately for all non-specific aspects of the treat-
ment experience. Various types of sham have been proposed in-
cluding deactivated units that are identical in appearance but de-
liver no actual stimulation to devices where an initial brief period
of stimulation at the start of use is delivered and then faded out.
To try to enhance blinding in these paradigms the information
given to participants is often limited regarding what they should
feel when the device is switched on. However, it is clear that there
are substantial threats to the credibility of these shams when com-
pared to active stimulation that elicits strong sensations. Given
that TENS effectiveness is widely thought to be related to the in-
tensity of the stimulus (Sluka 2013), a true sham that establishes
robust blinding of participants is not achievable. This represents
a risk of bias to all sham-controlled TENS trials.
Why it is important to do this overview
TENS is a widely-used and readily available adjunct therapy that
has been used and advocated clinically for many years to man-
age a range of painful conditions. Despite this, its effectiveness
remains controversial. There are a number of Cochrane reviews
that have assessed the TENS effectiveness in people with persis-
tent pain. There is a need to systematically synthesise the evidence
from these reviews to offer a clear summary of the evidence for
patients, clinicians and commissioners and to clearly reflect areas
of remaining uncertainty. There is also a need to critically scruti-
nise the evidence that is presented in the Cochrane Library and to
identify possible sources of inconsistency in the approaches taken
to evaluating the effectiveness of TENS, with a view to developing
strategies to improve consistency and quality.
O B J E C T I V E S
1. To provide an overview of evidence from Cochrane
systematic reviews of the effectiveness of TENS to reduce pain in
adults with chronic pain (excluding headache or migraine).
2. To provide an overview of evidence from Cochrane
systematic reviews of the safety of TENS to reduce pain in adults
with chronic pain (excluding headache or migraine).
3. To identify possible sources of inconsistency in the
approaches taken to evaluating the evidence related to TENS for
chronic pain (excluding headache or migraine) in the Cochrane
Library with a view to recommending strategies to improve
consistency.
4. To highlight areas of remaining uncertainty regarding the
effectiveness of TENS for chronic pain (excluding headache or
migraine) with a view to recommending strategies to reduce any
uncertainty.
M E T H O D S
Criteria for considering reviews for inclusion
We will include all Cochrane reviews of randomised controlled
trials (RCTs) that assessed the effectiveness of TENS in people
with chronic pain. In the event of overlap, where more than one
review includes evidence relating to the same comparisons for the
same conditions, we will compare each review to the most recent
review in order to establish whether the older review(s) identifies
any RCTs or data that are not included or adequately reported
in the most recent review. Where this is not the case, we will
not consider the comparisons in the older review(s). We will only
consider data from original studies presented in more than one
included review once in any new analyses.
Types of participants
Adults 18 years or older described as suffering from chronic pain
(of > 3 months duration) of any origin, excluding headache or
migraine.
Types of intervention
We will include reviews which have included studies of all stan-
dard modes of TENS, regardless of the device manufacturer, in
which the TENS condition delivers a clearly perceptible sensa-
tion. Given that self-use and portability are key clinical features of
TENS, we will not consider the evidence for non-portable elec-
trical stimulation devices, such as interferential therapy. We will
include evidence from studies that used any parameters of TENS
treatment. We will exclude studies where current was delivered
percutaneously (e.g. electroacupuncture, PENS, neuroreflexother-
apy). Where reviews include both comparisons of TENS but also
include these interventions that we plan to exclude, we will only
consider the evidence relating to TENS as defined above. Com-
parisons of interest are:
• TENS versus sham.
• TENS versus usual care or no treatment or waiting list
control.
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• TENS plus active intervention versus active intervention
alone.
• Comparisons between different types of TENS or TENS
delivered using different stimulation parameters.
Types of outcome measure
Primary outcomes
1. Changes in pain intensity as measured using a visual
analogue scale (VAS), numerical rating scale (NRS), verbal rating
scale or Likert scale.
2. Incidence and nature of adverse effects.
We will present follow-up scores of primary outcomes and anal-
yse them as between-group differences. Where data are available,
we will also present the outcome in a dichotomised format. For
dichotomised data (responder analyses), we will consider analyses
based upon a ≥ 30% reduction in pain to represent a moderately
important benefit, and a≥ 50% reduction in pain intensity to rep-
resent a substantially important benefit, as suggested by the Initia-
tive on Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) guidelines (Dworkin 2008).
The IMMPACT thresholds are based on estimates of the degree of
within-person change from baseline that participants might con-
sider to be clinically important, whereas the trials in this review
are most likely to present effect sizes as the average between-group
change between intervention-groups. There is little consensus or
evidence regarding what the threshold should be for a clinically
important difference in pain intensity based on the between-group
difference post-intervention. For some pharmacological interven-
tions the distribution of participant outcomes is bimodally dis-
tributed (Moore 2013; Moore 2014b; Moore 2014c). That is,
some patients experience a substantial reduction in symptoms,
some minimal to no improvement, and very few experience in-
termediate (moderate) improvements. In this instance, and if the
distribution of participant outcomes reflects the distribution of
treatment effects, then the average effect may be the effect that
the fewest participants actually demonstrate (Moore 2013). It is
therefore possible that a small average between-group effect size
might reflect that a proportion of participants responded very well
to the intervention tested. It is unknown whether outcomes are
commonly bimodally distributed in TENS trials and the advan-
tage of focusing on the between-group difference is that it is the
only direct estimate of the average specific effect of the interven-
tion. Equally it remains possible that a very small average between-
group effect might accurately represent generally very small effects
of an intervention for most or all individuals.
The OMERACT 12 group have reported recommendations for
minimally important difference for pain outcomes (Busse 2015).
They recommend a threshold of 10 mm on a 0 to 100 mmVAS as
the threshold for minimal importance for average between-group
change though stress that this should be interpreted with caution
as it remains possible that estimates which fall closely below this
point may still reflect a treatment that benefits an appreciable
number of patients. We will use this threshold but interpret it
appropriately and cautiously.
Secondary outcomes
We will analyse the following secondary outcome measures where
such data are available:
1. Changes in disability as measured by validated self-report
questionnaires or functional testing protocols.
2. Changes in health-related quality of life using any validated
tool (e.g. SF-36, EuroQoL).
3. Change in analgesic medication use.
4. Changes in patient global impression of change (PGIC)
scales.
Secondary outcomes will be similarly presented and analysed as
either change on a continuous scale or in a dichotomised format,
depending on what is presented in the included reviews.
Search methods for identification of reviews
Electronic searches
We will search the most recent version of the Cochrane Database
of Systematic Reviews (CDSR), via the Cochrane Library, across
all years. The search strategy is presented in Appendix 1.
Data collection and analysis
Selection of reviews
Two review authors (MJC and NEO) will independently screen
the results of the electronic search by title and abstract. We will
obtain the full-text versions of the reviews that are deemed ap-
propriate and will apply the selection criteria to determine final
inclusion. We will resolve any disagreements between review au-
thors through discussion. Where resolution is not achieved, a third
overview author (BMW) will consider the review in question and
we will make a majority decision.
Data extraction and management
Two review authors (MJC and NEO) will extract data indepen-
dently using a standardised form.Wewill resolve any discrepancies
by consensus. Where agreement cannot be reached, a third review
author (BMW) will consider the paper and we will make a major-
ity decision. The data extraction form will include the following
details:
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• Objectives of the review.
• Number of included trials.
• Details of the included participants.
• Details of the interventions studied.
• Outcomes and time points assessed (primary and
secondary).
• Comparisons performed and meta-analysis details.
• Details of the approach taken to assessing heterogeneity
including subgroup analyses.
• Whether stimulus intensity was titrated to ensure a strong
sensation.
• Assessment of the methodological quality and risk of bias of
the included evidence (as assessed and presented in each included
review).
• GRADE judgements regarding the quality of evidence
where present.
We will contact the authors of included reviews in the event that
we cannot extract the required information from the reports. We
do not plan on contacting authors of individual studies included
in the reviews.
Assessment of methodological quality of included
reviews
Wewill use the AMSTAR tool to assess themethodological quality
of the included reviews (Shea 2007; see Table 1). Two overview
authors (MJC and NEO) will assess review quality independently.
We will resolve any discrepancies by consensus. Where agreement
cannot be reached, a third overview author (BMW) will consider
the paper and we will make a majority decision. Included reviews
may assess the methodological quality and risk of bias of included
studies in a variety of ways. Therefore, we will use the judgements
made by the authors of the original included reviews regarding the
quality of evidence and risk of bias but report it critically within
the context of our assessment of the quality of the review itself.
Data synthesis
It is unlikely that additional data analysis will be required since
the included reviews should have undertaken appropriate analyses.
Where possible, we will extract data from the included reviews
and present it in a ’Summary of findings’ table. We will present
comparisons, where possible, according to clinical condition and
outcome. Comparisons of primary interest are as follows:
• TENS versus sham.
• TENS versus usual care or no treatment or waiting list
control.
• TENS plus active intervention versus active intervention
alone.
• Comparisons between different types of TENS or TENS
delivered using different stimulation parameters.
We will determine the precise comparisons presented by the con-
tent of the included reviews. Where possible, we will group ex-
tracted data according to clinical diagnosis, outcome and dura-
tion of follow-up (during-use effects; short-term: zero to < two
weeks post-intervention; mid-term: two to seven weeks post-in-
tervention; and long-term: ≥ eight weeks post-intervention). We
will present effect sizes using appropriate metrics including, where
possible, the number needed to treat for an additional beneficial
outcome (NNTB) and number needed to treat for an additional
harmful outcome (NNTH).
We will consider the findings of subgroup analyses presented by
the included reviews if they investigate the impact of clinical di-
agnosis or stimulation parameters on statistical heterogeneity and
effect size. Where included reviews have used the GRADE ap-
proach (Guyatt 2008) to summarise a body of evidence, we will
present their summary assessments. Where reviews do not provide
a GRADE assessment of the quality of evidence, we will perform
one using the following criteria:
• Limitations of studies: downgrade once if < 75% of
included studies are at low risk of bias across all ’Risk of bias’
criteria.
• Inconsistency: downgrade once if heterogeneity is
statistically significant and the I² statistic is ≥ 50%.
• Indirectness: downgrade once if > 50% of the participants
were outside the target group.
• Imprecision: downgraded once if there are < 400 subjects
for continuous data and < 300 events for dichotomous data
(Guyatt 2011).
• Publication bias: downgrade once where there is direct
evidence of publication bias.
We will present and discuss important limitations within the evi-
dence base and consider the possible influence of publication and
small study biases on review findings. Two review authors (MJC
and NEO) will independently apply the GRADE criteria. We
will resolve any disagreement between review authors through dis-
cussion. Where resolution is not achieved, a third review author
(BMW) will consider the judgement in question.
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A D D I T I O N A L T A B L E S
Table 1. AMSTAR review quality assessment tool
Criteria Specific requirements
1. Was an ’a priori’ design provided? The research question and inclusion criteria should be established
before the conduct of the review
2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a
consensus procedure for disagreements should be in place
3. Was a comprehensive literature search performed? At least two electronic sources should be searched.The reportmust
include years and databases used (e.g. Central, EMBASE, and
MEDLINE). Key words or MESH terms, or both, must be stated
and where feasible the search strategy should be provided. All
7Transcutaneous Electrical Nerve Stimulation (TENS) for chronic pain - an overview of Cochrane reviews (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. AMSTAR review quality assessment tool (Continued)
searches should be supplemented by consulting current contents,
reviews, textbooks, specialized registers or experts in the particular
field of study, and by reviewing the references in the studies found
4. Was the status of publication (i.e. grey literature) used as
an inclusion criterion?
The review authors should state that they searched for reports
regardless of their publication type. The review authors should
statewhether or not they excluded any reports (from the systematic
review), based on their publication status, language etc
5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided.
6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original
studies should be provided on the participants, interventions and
outcomes. The ranges of characteristics in all the studies analysed
e.g. age, race, sex, relevant socioeconomic data, disease status,
duration, severity or other diseases should be reported
7. Was the scientific quality of the included studies assessed
and documented?
’A priori’ methods of assessment should be provided (e.g. for ef-
fectiveness studies if the review author(s) chose to include only
randomised, double-blind, placebo controlled studies, or alloca-
tion concealment as inclusion criteria); for other types of studies
alternative items will be relevant
8. Was the scientific quality of the included studies used ap-
propriately in formulating conclusions?
The results of the methodological rigor and scientific quality
should be considered in the analysis and the conclusions of the
review, and explicitly stated in formulating recommendations
9. Were the methods used to combine the findings of studies
appropriate?
For the pooled results, a test should be done to ensure the studies
were combinable, to assess their homogeneity (i.e. Chi² test for
homogeneity, I² statistic). If heterogeneity exists a random-effects
model should be used or the clinical appropriateness of combining
should be taken into consideration (i.e. is it sensible to combine?
), or both
10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of
graphical aids (e.g. funnel plot, other available tests) or statistical
tests (e.g. Egger regression test), or both
11. Was the conflict of interest stated? Potential sources of support should be clearly acknowledged in
both the systematic review and the included studies
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A P P E N D I C E S
Appendix 1. CDSR search strategy
1. MeSH descriptor: [Transcutaneous Electric Nerve Stimulation] explode all trees
2 (“TENS” or “TNS” or “ENS”) ti,ab,kw
3 (“TENS” or “TNS” or “ENS”) ti,ab,kw
4 (“transcutaneous electric* nerve stimulation” or “transcutaneous nerve stimulation”) ti,ab,kw
5 (“electric* nerve stimulation” or “electrostimulation therap*” or “electro-stimulation therap*”) ti,ab,kw
6 (“electric* nerve therap*” or electroanalgesi*) ti,ab,kw
7 transcutaneous electric* stimulation ti,ab,kw
8 TES ti,ab,kw
9 or/1-8
10 MeSH descriptor: [Pain] explode all trees
11 9 and 10
WH A T ’ S N E W
Date Event Description
1 October 2015 Amended Minor corrections.
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